WANJIA GROUP(00401.HK)

Company Encyclopedia
View More
name
WANJIA GROUP
00401.HK
Wanjia Group Holdings Limited, an investment holding company, engages in the wholesale and distribution pharmaceutical business in the Mainland China and Hong Kong. The company offers hemodialysis treatment and consultancy services. It sells its products to hospitals and healthcare institutions; and companies operating pharmaceutical retail chain stores, independent pharmacies, outpatient departments of community hospitals, healthcare service stations, and clinics. Wanjia Group Holdings Limited was founded in 2004 and is headquartered in Kowloon, Hong Kong.
169.31 B
00401.HKMarket value -Rank by Market Cap -/-

Financial Score

04/01/2026 Update
C
Health Care DistributorsIndustry
Industry Ranking16/21
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-11.91%D
    • Profit Margin-5.24%D
    • Gross Margin30.07%C
  • Growth ScoreD
    • Revenue YoY-4.50%D
    • Net Profit YoY75.94%A
    • Total Assets YoY-10.75%E
    • Net Assets YoY-12.62%E
  • Cash ScoreE
    • Cash Flow Margin-1907.08%E
    • OCF YoY-4.50%D
  • Operating ScoreA
    • Turnover1.43A
  • Debt ScoreB
    • Gearing Ratio36.40%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    WANJIA GROUP offers a rights issue at a discount of 31.62%, raising at least HKD 40.82 million

    WANJIA GROUP announced a proposed one-for-one rights issue, issuing at least 560 million shares; the rights issue price is HKD 0.08, representing a discount of 31.62% compared to the last trading day (30th). The net proceeds are not less than HKD 40.82 million, intended for the development of existing pharmaceutical wholesale and distribution business, as well as blood dialysis treatment and consulting services business and potential investment opportunities; repayment of amounts owed to a director; and general working capital

    AASTOCKS·
    HK
    00401
    +2.13%
    AASTOCKS·
    HK
    00401
    +2.13%

    Wanjia Group Proposes Rights Issue

    Wanjia Group Holdings Ltd :PROPOSES RIGHTS ISSUE OF 1 RIGHTS SHARE FOR EVERY 1 SHARE HELD AT SUBSCRIPTION PRICE OF HK$0.08 PER SHARETO RAISE NOT LESS THAN HK$44.82 MILLION UNDER RIGHTS ISSUE

    Reuters·
    HK
    00401
    +2.13%
    Reuters·
    HK
    00401
    +2.13%

    Wanjia Group to Double Authorised Share Capital and Launch HK$40–47 Million Rights Issue

    Wanjia Group Holdings Ltd. plans to double its authorized share capital from HK$50 million to HK$100 million, pending shareholder approval. The company will also launch a rights issue of one new share for every existing share at HK$0.08 per share, aiming to raise approximately HK$40.82 million to HK$47.28 million. This move is intended to strengthen the company's capital base and provide funding flexibility, though it may lead to equity dilution for existing shareholders. The current analyst rating for the stock is a Hold with a price target of HK$0.14.

    Tip Ranks·
    HK
    00401
    +2.13%
    Tip Ranks·
    HK
    00401
    +2.13%

    Little Excitement Around Wanjia Group Holdings Limited's (HKG:401) Revenues As Shares Take 27% Pounding

    Wanjia Group Holdings Limited's shares have dropped 27% in the past month, despite a 116% gain over the past year. The company's low price-to-sales ratio of 0.4x, compared to the industry average above 1x, reflects its declining revenue, which fell 4.5% last year and 6.3% over three years. This decline contrasts with the industry's expected 9.2% growth, suggesting potential future challenges for the stock's valuation.

    Simplywall·
    HK
    00401
    +2.13%
    Simplywall·
    HK
    00401
    +2.13%

    Wanjia Group Holdings Reports Revenue Growth but Faces Operational Loss

    Wanjia Group Holdings Ltd. reported revenue growth driven by its Hemodialysis Business for the six months ended September 30, 2025. Despite this, the company faced an operational loss of HK$0.712 million, with no interim dividend declared, highlighting financial challenges. The company is listed on the Hong Kong Stock Exchange and focuses on healthcare, specifically Hemodialysis.

    Tip Ranks·
    HK
    00401
    +2.13%
    Tip Ranks·
    HK
    00401
    +2.13%
    © 2026 Longbridge｜Disclaimer